Companies › Intra-IMMUSG Pte
1 active drug program in 5 registered trials: 3 Phase 2, 2 Phase 1; Oncology, Ophthalmology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| PRL3-zumab Humanized monoclonal antibody targeting phosphatase of regenerating liver-3 (PRL3) | PRL3 | Phase 2 | Advanced Malignant Solid Tumor; Solid Tumor; Advanced Solid Cancers; Neovascular Age Related Macular Degeneration … | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07541001 | PRL3-zumab | Phase 2 | Advanced Malignant Solid Tumor | Oncology | Dec 2026 |
| NCT04452955 | PRL3-zumab | Phase 2 | Solid Tumor | Oncology | Dec 2026 |
| NCT07290088 | PRL3-zumab | Phase 2 | Advanced Solid Cancers | Oncology | Dec 2026 |
| NCT07547228 | PRL3-zumab | Phase 1 | Neovascular Age Related Macular Degeneration | Ophthalmology | Feb 2027 |
| NCT03191682 | PRL3-zumab | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2027 |
–
CrystalGenomics Partner Therapeutics STCube Ambrx Convergent Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.